Each tablet contains: Glipizide 5 mg.
Pharmacology: Pharmacokinetics: Glipizide is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring 1 to 3 hours after a single dose. It is extensively bound to plasma proteins and has a half life of about 2 to 4 hours. It is metabolized mainly in the liver and excreted chiefly in the urine, largely as inactive metabolites.
Glipizide is indicated in the treatment of type 2 diabetes mellitus.
Glipizide tablet is taken orally. The usual initial dose is 2.5-5 mg daily given as a single dose about 30 minutes before breakfast. Dosage may be adjusted at intervals of several days by amounts of 2.5-5 mg daily, to a maximum of 20 mg daily. Doses larger than 15 mg daily are given in two divided doses before meals.
Or as prescribed by the physician.
Glipizide is contraindicated in patients with ketoacidosis and in those with severe infection, trauma, or other severe conditions where sulfonylurea is unlikely to control the hyperglycemia; insulin should be administered in such situations.
Sulfonylureas should not be used in type 1 diabetes mellitus. Glipizide should not be given to breastfeeding mothers. Glipizide should also be avoided in patients with impairment of renal or hepatic function.
Gastrointestinal disturbances such as nausea, vomiting, heartburn, anorexia, diarrhea, and a metallic taste may occur and are usually mild and dose-dependent; increased appetite and weight gain may occur. Skin rashes and pruritus may occur and photosensitivity has been reported. Rashes are usually hypersensitivity reactions and may progress to more serious disorders.
A diminished hypoglycemic effect, has been seen or might be expected on theoretical grounds with adrenaline, aminoglutethimide, chlorpromazine, corticosteroids, diazoxide, oral contraceptives, rifamycins, thiazide diuretics, and thyroid hormones.
An increased hypoglycemic effect has occurred or might be expected with ACE inhibitors, alcohol, allopurinol, some analgesics (notably azapropazone, phenylbutazone, and the salicylates), azole antifungals (fluconazole, ketoconazole, and miconazole), chloramphenicol, cimetidine, clofibrate and related compounds, coumarin anticoagulants, fluoroquinolones, heparin, MAOIs, octreotide (although this may also produce hyperglycemia), ranitidine, sulfinpyrazone, sulfonamides (including co-trimoxazole), tetracyclines and tricyclic antidepressants.
Store at temperatures not exceeding 30°C. Protect from light.
A10BB07 - glipizide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.